The Medicines Company (MDCO) : Traders are negative on The Medicines Company (MDCO), as it has 15.6% of short positions outstanding compared to its float. The total shorts have reduced by -2,054,706 shares, which is a -16.2% reduction. From Jul 29, 2016, to August 15, 2016, the shorts came down from,12,669,036 to 10,614,330 shares. While the daily trading volume of the stock is 550,851, there are 19 days remaining to cover the open short positions. The short interest indicates that the traders dont see a large downside in the stock from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
The Medicines Company (NASDAQ:MDCO): The stock opened at $39.79 on Wednesday but the bulls could not build on the opening and the stock topped out at $40.55 for the day. The stock traded down to $38.59 during the day, due to lack of any buying support eventually closed down at $39.04 with a loss of -1.36% for the day. The stock had closed at $39.58 on the previous day. The total traded volume was 1,277,102 shares.
In a related news,The director of Medicines Co /De, Shigeta Hiroaki sold 3,849 shares at $38.5 on July 11, 2016. The Insider selling transaction had a total value worth of $148,187. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.